Oklahoma 2024 Regular Session

Oklahoma Senate Bill SB1216 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	SENATE FLOOR VERSION - SB1216 SFLR Page 1
4		-	(Bold face denotes Committee Amendments) 1
	3	+	Req. No. 2394 Page 1 1
5	4		2
6	5		3
7	6		4
8	7		5
9	8		6
10	9		7
11	10		8
12	11		9
13	12		10
14	13		11
15	14		12
16	15		13
17	16		14
18	17		15
19	18		16
20	19		17
21	20		18
22	21		19
23	22		20
24	23		21
25	24		22
26	25		23
27	26		24
28	27
29		-	SENATE FLOOR VERSION
30		-	February 22, 2024
	28	+	STATE OF OKLAHOMA
31	29
	30	+	2nd Session of the 59th Legislature (2024)
32	31
33		-	SENATE BILL ~~NO.~~ 1216 By: Standridge
	32	+	SENATE BILL 1216 By: Standridge
34	33
35	34
36	35
37	36
	37	+
	38	+	AS INTRODUCED
38	39
39	40		An Act relating to the Uniform Controlled Danger ous
40	41		Substances Act; amending 63 O.S. 2021, Section 2 -204,
41	42		as amended by Section 1 , Chapter 120, O.S.L. 2023 (63
42	43		O.S. Supp. 2023, Section 2 -204), which relates to
43	44		Schedule I controlled substances; adding substances
44	45		to list of Schedule I controlled substances ; updating
45	46		statutory reference; and providing an effective date.
46	47
47	48
48	49
49	50
50	51
51	52		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
52	53		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -204, as
53	54		amended by Section 1, Chapter 120, O.S.L. 2023 (63 O.S. Supp. 2023,
54	55		Section 2-204), is amended to read as follows:
55	56		Section 2-204. The controlled substances listed in this section
56	57		are included in Schedule I and include any material, compound,
57	58		mixture or preparation that contains any quan tity of the following
58	59		hallucinogenic substances, their salts, isomers and salts of
59	60		isomers, unless specifically excepted, when the existence of these
60	61		salts, isomers and salts of isomers is possible within the specific
61	62		chemical designation.
62		-	A. Any of the following opiates including their isomers,
63		-	esters, ethers, salts, and salts of isomers, esters, a nd ethers,
64	63
65		-	SENATE FLOOR VERSION - SB1216 SFLR Page 2
66		-	(Bold face denotes Committee Amendments) 1
	64	+	Req. No. 2394 Page 2 1
67	65		2
68	66		3
69	67		4
70	68		5
71	69		6
72	70		7
73	71		8
74	72		9
75	73		10
76	74		11
77	75		12
78	76		13
79	77		14
80	78		15
81	79		16
82	80		17
83	81		18
84	82		19
85	83		20
86	84		21
87	85		22
88	86		23
89	87		24
90	88
	89	+	A. Any of the following opiates including their isomers,
	90	+	esters, ethers, salts, and salts of isomers, esters, and ethers,
91	91		unless specifically excepted, when the existence of these isomers,
92	92		esters, ethers, and salts is possible within the specific chemical
93	93		designation:
94	94		1. Acetylmethadol;
95	95		2. Allylprodine;
96	96		3. Alphacetylmethadol;
97	97		4. Alphameprodine;
98	98		5. Alphamethadol;
99	99		6. Benzethidine;
100	100		7. Betacetylmethadol;
101	101		8. Betameprodine;
102	102		9. Betamethadol;
103	103		10. Betaprodine;
104	104		11. Clonitazene;
105	105		12. Dextromoramide;
106	106		13. Dextrorphan (except its methyl ether);
107	107		14. Diampromide;
108	108		15. Diethylthiambutene;
109	109		16. Dimenoxadol;
110	110		17. Dimepheptanol;
111	111		18. Dimethylthiambutene;
112	112		19. Dioxaphetyl butyrate;
113		-	20. Dipipanone;
114		-	21. Ethylmethylthiambutene;
115	113
116		-	SENATE FLOOR VERSION - SB1216 SFLR Page 3
117		-	(Bold face denotes Committee Amendments) 1
	114	+	Req. No. 2394 Page 3 1
118	115		2
119	116		3
120	117		4
121	118		5
122	119		6
123	120		7
124	121		8
125	122		9
126	123		10
127	124		11
128	125		12
129	126		13
130	127		14
131	128		15
132	129		16
133	130		17
134	131		18
135	132		19
136	133		20
137	134		21
138	135		22
139	136		23
140	137		24
141	138
	139	+	20. Dipipanone;
	140	+	21. Ethylmethylthiambutene;
142	141		22. Etonitazene;
143	142		23. Etoxeridine;
144	143		24. Furethidine;
145	144		25. Hydroxypethidine;
146	145		26. Isotonitazene;
147	146		27. Ketobemidone;
148	147		28. Levomoramide;
149	148		29. Levophenacylmorphan;
150	149		30. Metonitazene;
151	150		31. Morpheridine;
152	151		32. N-desethyl isotonitazene;
153	152		33. N-pyrrolidino protonitazene ;
154	153		34. Noracymethadol;
155	154		34. 35. Norlevorphanol;
156	155		35. 36. Normethadone;
157	156		36. 37. Norpipanone;
158	157		37. 38. Phenadoxone;
159	158		38. 39. Phenampromide;
160	159		39. 40. Phenomorphan;
161	160		40. 41. Phenoperidine;
162	161		41. 42. Piritramide;
163	162		42. 43. Proheptazine;
164		-	43. 44. Properidine;
165		-	44. 45. Protonitazene;
166	163
167		-	SENATE FLOOR VERSION - SB1216 SFLR Page 4
168		-	(Bold face denotes Committee Amendments) 1
	164	+	Req. No. 2394 Page 4 1
169	165		2
170	166		3
171	167		4
172	168		5
173	169		6
174	170		7
175	171		8
176	172		9
177	173		10
178	174		11
179	175		12
180	176		13
181	177		14
182	178		15
183	179		16
184	180		17
185	181		18
186	182		19
187	183		20
188	184		21
189	185		22
190	186		23
191	187		24
192	188
	189	+	43. 44. Properidine;
	190	+	44. 45. Protonitazene;
193	191		45. 46. Racemoramide; or
194	192		46. 47. Trimeperidine.
195	193		B. Any of the following opium derivatives , their salts,
196	194		isomers, and salts of isomers, unless specifi cally excepted, when
197	195		the existence of these salts, isomers, and salts of isomers is
198	196		possible within the specific chemical designation:
199	197		1. Acetorphine;
200	198		2. Acetyldihydrocodeine;
201	199		3. Benzylmorphine;
202	200		4. Codeine methylbromide;
203	201		5. Codeine-N-Oxide;
204	202		6. Cyprenorphine;
205	203		7. Desomorphine;
206	204		8. Dihydromorphine;
207	205		9. Etorphine;
208	206		10. Heroin;
209	207		11. Hydromorphinol;
210	208		12. Methyldesorphine;
211	209		13. Methylhydromorphine;
212	210		14. Morphine methylbromide;
213	211		15. Morphine methylsulfonate;
214	212		16. Morphine-N-Oxide;
215		-	17. Myrophine;
216		-	18. Nicocodeine;
217	213
218		-	SENATE FLOOR VERSION - SB1216 SFLR Page 5
219		-	(Bold face denotes Committee Amendments) 1
	214	+	Req. No. 2394 Page 5 1
220	215		2
221	216		3
222	217		4
223	218		5
224	219		6
225	220		7
226	221		8
227	222		9
228	223		10
229	224		11
230	225		12
231	226		13
232	227		14
233	228		15
234	229		16
235	230		17
236	231		18
237	232		19
238	233		20
239	234		21
240	235		22
241	236		23
242	237		24
243	238
	239	+	17. Myrophine;
	240	+	18. Nicocodeine;
244	241		19. Nicomorphine;
245	242		20. Normorphine;
246	243		21. Phoclodine;
247	244		22. Thebacon;
248	245		23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
249	246		(Acetyl fentanyl);
250	247		24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
251	248		(Crotonyl fentanyl);
252	249		25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
253	250		furancarboxamide (Furanyl fentanyl);
254	251		26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
255	252		27. N-(1-phenethylpiperidin-4-yl)-N-
256	253		phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
257	254		28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
258	255		(Butyrl fentanyl).
259	256		C. Any material, compound, mixture, or preparation which
260	257		contains any quantity of the following hallucinogenic substances,
261	258		their salts, isomers, and salts of isomers, unless specifically
262	259		excepted, when the ex istence of these salts, isomers, and salts of
263	260		isomers is possible within the specific chemical design ation:
264	261		1. Methcathinone;
265	262		2. 3, 4-methylenedioxy amphetamine;
266		-	3. 3, 4-methylenedioxy methamphetamine;
267		-	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
268	263
269		-	SENATE FLOOR VERSION - SB1216 SFLR Page 6
270		-	(Bold face denotes Committee Amendments) 1
	264	+	Req. No. 2394 Page 6 1
271	265		2
272	266		3
273	267		4
274	268		5
275	269		6
276	270		7
277	271		8
278	272		9
279	273		10
280	274		11
281	275		12
282	276		13
283	277		14
284	278		15
285	279		16
286	280		17
287	281		18
288	282		19
289	283		20
290	284		21
291	285		22
292	286		23
293	287		24
294	288
	289	+	3. 3, 4-methylenedioxy methamphetamine;
	290	+	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
295	291		5. 3, 4, 5-trimethoxy amphetamine;
296	292		6. Bufotenine;
297	293		7. Diethyltryptamine;
298	294		8. Dimethyltryptamine;
299	295		9. 4-methyl-2, 5-dimethoxyamphetamine;
300	296		10. Ibogaine;
301	297		11. Lysergic acid diethylamide;
302	298		12. Marijuana;
303	299		13. Mescaline;
304	300		14. N-benzylpiperazine;
305	301		15. N-ethyl-3-piperidyl benzilate;
306	302		16. N-methyl-3-piperidyl benzilate;
307	303		17. Psilocybin;
308	304		18. Psilocyn;
309	305		19. 2, 5 dimethoxyamphetamine;
310	306		20. 4 Bromo-2, 5-dimethoxyamphetamine;
311	307		21. 4 methoxyamphetamine;
312	308		22. Cyclohexamine;
313	309		23. Salvia Divinorum;
314	310		24. Salvinorin A;
315		-	25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
316		-	thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
317		-	TPCP, TCP;
318		-	26. Phencyclidine (PCP);
319	311
320		-	SENATE FLOOR VERSION - SB1216 SFLR Page 7
321		-	(Bold face denotes Committee Amendments) 1
	312	+	Req. No. 2394 Page 7 1
322	313		2
323	314		3
324	315		4
325	316		5
326	317		6
327	318		7
328	319		8
329	320		9
330	321		10
331	322		11
332	323		12
333	324		13
334	325		14
335	326		15
336	327		16
337	328		17
338	329		18
339	330		19
340	331		20
341	332		21
342	333		22
343	334		23
344	335		24
345	336
	337	+	25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
	338	+	thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
	339	+	TPCP, TCP;
	340	+	26. Phencyclidine (PCP);
346	341		27. Pyrrolidine Analog for Phencyclidine . Also known as 1-(1-
347	342		Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
348	343		28. 1-(3-trifluoromethylphenyl) piperazine;
349	344		29. Flunitrazepam;
350	345		30. B-hydroxy-amphetamine;
351	346		31. B-ketoamphetamine;
352	347		32. 2,5-dimethoxy-4-nitroamphetamine;
353	348		33. 2,5-dimethoxy-4-bromophenethylamine;
354	349		34. 2,5-dimethoxy-4-chlorophenethylamine;
355	350		35. 2,5-dimethoxy-4-iodoamphetamine;
356	351		36. 2,5-dimethoxy-4-iodophenethylamine;
357	352		37. 2,5-dimethoxy-4-methylphenethylamine;
358	353		38. 2,5-dimethoxy-4-ethylphenethylamine;
359	354		39. 2,5-dimethoxy-4-fluorophenethylamine;
360	355		40. 2,5-dimethoxy-4-nitrophenethylamine;
361	356		41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
362	357		42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
363	358		43. 2,5-dimethoxy-4-propylthio-phenethylamine;
364	359		44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
365	360		45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
366		-	46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
367		-	47. 5-methoxy-N, N-dimethyltryptamine;
368		-	48. N-methyltryptamine;
369		-	49. A-ethyltryptamine;
370	361
371		-	SENATE FLOOR VERSION - SB1216 SFLR Page 8
372		-	(Bold face denotes Committee Amendments) 1
	362	+	Req. No. 2394 Page 8 1
373	363		2
374	364		3
375	365		4
376	366		5
377	367		6
378	368		7
379	369		8
380	370		9
381	371		10
382	372		11
383	373		12
384	374		13
385	375		14
386	376		15
387	377		16
388	378		17
389	379		18
390	380		19
391	381		20
392	382		21
393	383		22
394	384		23
395	385		24
396	386
	387	+	46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
	388	+	47. 5-methoxy-N, N-dimethyltryptamine;
	389	+	48. N-methyltryptamine;
	390	+	49. A-ethyltryptamine;
397	391		50. A-methyltryptamine;
398	392		51. N, N-diethyltryptamine;
399	393		52. N, N-diisopropyltryptamine;
400	394		53. N, N-dipropyltryptamine;
401	395		54. 5-methoxy-a-methyltryptamine;
402	396		55. 4-hydroxy-N, N-diethyltryptamine;
403	397		56. 4-hydroxy-N, N-diisopropyltryptamine;
404	398		57. 5-methoxy-N, N-diisopropyltryptamine;
405	399		58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
406	400		59. 3,4-Methylenedioxymethcathinone (Methylone);
407	401		60. 3,4-Methylenedioxypyrovalerone (MDPV);
408	402		61. 3-Methylmethcathinone (Metaphedrone);
409	403		62. 4-Methylmethcathinone (Mephedrone);
410	404		62. 63. 4-methoxymethcathinone;
411	405		63. 64. 4-Fluoromethcathinone;
412	406		64. 65. 3-Fluoromethcathinone;
413	407		65. 66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-
414	408		aminopropane;
415	409		66. 67. 2,5-Dimethoxy-4-chloroamphetamine;
416	410		67. 68. 4-Methylethcathinone;
417		-	68. 69. Pyrovalerone;
418		-	69. 70. N,N-diallyl-5-methoxytryptamine;
419		-	70. 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
420		-	71. 72. B-keto-N-Methylbenzodioxolylbuta namine (Butylone);
421	411
422		-	SENATE FLOOR VERSION - SB1216 SFLR Page 9
423		-	(Bold face denotes Committee Amendments) 1
	412	+	Req. No. 2394 Page 9 1
424	413		2
425	414		3
426	415		4
427	416		5
428	417		6
429	418		7
430	419		8
431	420		9
432	421		10
433	422		11
434	423		12
435	424		13
436	425		14
437	426		15
438	427		16
439	428		17
440	429		18
441	430		19
442	431		20
443	432		21
444	433		22
445	434		23
446	435		24
447	436
	437	+	68. 69. Pyrovalerone;
	438	+	69. 70. N,N-diallyl-5-methoxytryptamine;
	439	+	70. 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
	440	+	71. 72. B-keto-N-Methylbenzodioxolylbutanamine ( Butylone);
448	441		72. 73. B-keto-Methylbenzodioxolylpentanamine ( Pentylone);
449	442		73. 74. Alpha-Pyrrolidinopentiophenone;
450	443		74. 75. 4-Fluoroamphetamine;
451	444		75. 76. Pentedrone;
452	445		76. 77. 4’-Methyl-a-pyrrolidinohexaphenone;
453	446		77. 78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
454	447		78. 79. 2,5-dimethoxyphenethylamine;
455	448		79. 80. 1,4-Dibenzylpiperazine;
456	449		80. 81. N,N-Dimethylamphetamine;
457	450		81. 82. 4-Fluoromethamphetamine;
458	451		82. 83. 4-Chloro-2,5-dimethoxy-N-(2-
459	452		methoxybenzyl)phenethylamine (25C-NBOMe);
460	453		83. 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)pheneth ylamine
461	454		(25I-NBOMe);
462	455		84. 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
463	456		(25B-NBOMe);
464	457		85. 86. 1-(4-Fluorophenyl)piperazine;
465	458		86. 87. Methoxetamine;
466	459		87. 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
467	460		methylbenzamide;
468		-	88. 89. N-ethyl hexadrone;
469		-	89. 90. Isopropyl-U-47700;
470		-	90. 91. Para-fluorobutyrl fentanyl;
471		-	92. Para-fluorofentanyl (pFF);
472	461
473		-	SENATE FLOOR VERSION - SB1216 SFLR Page 10
474		-	(Bold face denotes Committee Amendments) 1
	462	+	Req. No. 2394 Page 10 1
475	463		2
476	464		3
477	465		4
478	466		5
479	467		6
480	468		7
481	469		8
482	470		9
483	471		10
484	472		11
485	473		12
486	474		13
487	475		14
488	476		15
489	477		16
490	478		17
491	479		18
492	480		19
493	481		20
494	482		21
495	483		22
496	484		23
497	485		24
498	486
	487	+	88. 89. N-ethyl hexadrone;
	488	+	89. 90. Isopropyl-U-47700;
	489	+	90. 91. Para-fluorobutyrl fentanyl;
	490	+	92. Para-fluorofentanyl (pFF);
499	491		91. 93. Fluoro isobutryrl fentanyl;
500	492		92. 94. 3-Hydroxy Phencyclidine (PCP);
501	493		93. 95. 3-methoxy Phencyclidine (PCP);
502	494		94. 96. Flualprazolam; or
503	495		95. 97. Flubromazolam.
504	496		D. Unless specifically excepted or unless listed in a di fferent
505	497		schedule, any material, compound, mixtur e, or preparation which
506	498		contains any quantit y of the following substances having stimulant
507	499		or depressant effect on the central nervous system:
508	500		1. Fenethylline;
509	501		2. Mecloqualone;
510	502		3. N-ethylamphetamine;
511	503		4. Methaqualone;
512	504		5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
513	505		hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
514	506		oxybate, and sodium oxybutyrate;
515	507		6. Gamma-Butyrolactone (GBL) as packaged, marketed,
516	508		manufactured or promoted for human consumption, with the exception
517	509		of legitimate food additive and manufacturing purposes;
518		-	7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
519		-	manufactured for human consumption, wit h the exception of legitimate
520		-	food additive and manufacturing purposes ;
521	510
522		-	SENATE FLOOR VERSION - SB1216 SFLR Page 11
523		-	(Bold face denotes Committee Amendments) 1
	511	+	Req. No. 2394 Page 11 1
524	512		2
525	513		3
526	514		4
527	515		5
528	516		6
529	517		7
530	518		8
531	519		9
532	520		10
533	521		11
534	522		12
535	523		13
536	524		14
537	525		15
538	526		16
539	527		17
540	528		18
541	529		19
542	530		20
543	531		21
544	532		22
545	533		23
546	534		24
547	535
	536	+	7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
	537	+	manufactured for human consumption, wit h the exception of legitimate
	538	+	food additive and manufacturing purposes ;
548	539		8. Gamma Valerolactone (GVL) as packaged, marketed, or
549	540		manufactured for human consumption , with the exception of legitimate
550	541		food additive and manufacturing purposes;
551	542		9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
552	543		manufactured, or promoted for human consumption with the exception
553	544		of legitimate manufacturing purposes; or
554	545		10. N-ethylpentylone.
555	546		E. 1. The following industrial uses of Gamma-Butyrolactone,
556	547		Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
557	548		excluded from all schedule s of controlled substances under this
558	549		title:
559	550		a. pesticides,
560	551		b. photochemical etching,
561	552		c. electrolytes of small batteries or capacitors,
562	553		d. viscosity modifiers in polyurethane,
563	554		e. surface etching of metal coated plastics,
564	555		f. organic paint disbursements for water soluble inks,
565	556		g. pH regulators in the dyeing of wool and polyamide
566	557		fibers,
567	558		h. foundry chemistry as a catalyst during curing,
568		-	i. curing agents in many coating systems based on
569		-	urethanes and amides,
570		-	j. additives and flavoring agents in food, c onfectionary,
571		-	and beverage products,
572	559
573		-	SENATE FLOOR VERSION - SB1216 SFLR Page 12
574		-	(Bold face denotes Committee Amendments) 1
	560	+	Req. No. 2394 Page 12 1
575	561		2
576	562		3
577	563		4
578	564		5
579	565		6
580	566		7
581	567		8
582	568		9
583	569		10
584	570		11
585	571		12
586	572		13
587	573		14
588	574		15
589	575		16
590	576		17
591	577		18
592	578		19
593	579		20
594	580		21
595	581		22
596	582		23
597	583		24
598	584
	585	+	i. curing agents in many coating systems based on
	586	+	urethanes and amides,
	587	+	j. additives and flavoring agents in food, c onfectionary,
	588	+	and beverage products,
599	589		k. synthetic fiber and clothing production,
600	590		l. tetrahydrofuran production,
601	591		m. gamma butyrolactone production,
602	592		n. polybutylene terephthalate resin production,
603	593		o. polyester raw materials for polyurethane elastomers
604	594		and foams,
605	595		p. coating resin raw materi al, and
606	596		q. as an intermediate in the manufacture of other
607	597		chemicals and pharmaceuticals.
608	598		2. At the request of any person, the Director of the Oklahoma
609	599		State Bureau of Narcotics and Dan gerous Drugs Control may exempt any
610	600		other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
611	601		Gamma Valerolactone, or 1,4 Butanedi ol from being included as a
612	602		Schedule I controlled substance if such p roduct is labeled,
613	603		marketed, manufactured and distributed for legitimate industrial use
614	604		in a manner that reduces or eliminates the likelihood of abuse.
615	605		3. In making a determination regar ding an industrial product,
616	606		the Director, after notice and hearing, s hall consider the
617	607		following:
618	608		a. the history and current pattern of abuse,
619		-	b. the name and labeling of the product,
620		-	c. the intended manner of distribution, advertising and
621		-	promotion of the product, and
622	609
623		-	SENATE FLOOR VERSION - SB1216 SFLR Page 13
624		-	(Bold face denotes Committee Amendments) 1
	610	+	Req. No. 2394 Page 13 1
625	611		2
626	612		3
627	613		4
628	614		5
629	615		6
630	616		7
631	617		8
632	618		9
633	619		10
634	620		11
635	621		12
636	622		13
637	623		14
638	624		15
639	625		16
640	626		17
641	627		18
642	628		19
643	629		20
644	630		21
645	631		22
646	632		23
647	633		24
648	634
	635	+	b. the name and labeling of the product,
	636	+	c. the intended manner of distribution, advertising and
	637	+	promotion of the product, and
649	638		d. other factors as may be relevant to and consistent
650	639		with the public health and safety.
651	640		4. The hearing shall be held in accordance with the procedures
652	641		of the Administrative Procedures Act.
653	642		F. Any material, compound, mixture, or preparation , whether
654	643		produced directly or indirectly from a substance of vegetab le origin
655	644		or independently by means of chemical synthesis, or by a combination
656	645		of extraction and chemical synthesis, that contains any quantity of
657	646		the following substances, or that contai ns any of their salts,
658	647		isomers, and salts of isomers when the existen ce of these salts,
659	648		isomers, and salts of isomers is possible within the specific
660	649		chemical designation:
661	650		1. JWH-004;
662	651		2. JWH-007;
663	652		3. JWH-009;
664	653		4. JWH-015;
665	654		5. JWH-016;
666	655		6. JWH-018;
667	656		7. JWH-019;
668	657		8. JWH-020;
669	658		9. JWH-030;
670		-	10. JWH-046;
671		-	11. JWH-047;
672		-	12. JWH-048;
673	659
674		-	SENATE FLOOR VERSION - SB1216 SFLR Page 14
675		-	(Bold face denotes Committee Amendments) 1
	660	+	Req. No. 2394 Page 14 1
676	661		2
677	662		3
678	663		4
679	664		5
680	665		6
681	666		7
682	667		8
683	668		9
684	669		10
685	670		11
686	671		12
687	672		13
688	673		14
689	674		15
690	675		16
691	676		17
692	677		18
693	678		19
694	679		20
695	680		21
696	681		22
697	682		23
698	683		24
699	684
	685	+	10. JWH-046;
	686	+	11. JWH-047;
	687	+	12. JWH-048;
700	688		13. JWH-049;
701	689		14. JWH-050;
702	690		15. JWH-070;
703	691		16. JWH-071;
704	692		17. JWH-072;
705	693		18. JWH-073;
706	694		19. JWH-076;
707	695		20. JWH-079;
708	696		21. JWH-080;
709	697		22. JWH-081;
710	698		23. JWH-082;
711	699		24. JWH-094;
712	700		25. JWH-096;
713	701		26. JWH-098;
714	702		27. JWH-116;
715	703		28. JWH-120;
716	704		29. JWH-122;
717	705		30. JWH-145;
718	706		31. JWH-146;
719	707		32. JWH-147;
720	708		33. JWH-148;
721		-	34. JWH-149;
722		-	35. JWH-150;
723		-	36. JWH-156;
724	709
725		-	SENATE FLOOR VERSION - SB1216 SFLR Page 15
726		-	(Bold face denotes Committee Amendments) 1
	710	+	Req. No. 2394 Page 15 1
727	711		2
728	712		3
729	713		4
730	714		5
731	715		6
732	716		7
733	717		8
734	718		9
735	719		10
736	720		11
737	721		12
738	722		13
739	723		14
740	724		15
741	725		16
742	726		17
743	727		18
744	728		19
745	729		20
746	730		21
747	731		22
748	732		23
749	733		24
750	734
	735	+	34. JWH-149;
	736	+	35. JWH-150;
	737	+	36. JWH-156;
751	738		37. JWH-167;
752	739		38. JWH-175;
753	740		39. JWH-180;
754	741		40. JWH-181;
755	742		41. JWH-182;
756	743		42. JWH-184;
757	744		43. JWH-185;
758	745		44. JWH-189;
759	746		45. JWH-192;
760	747		46. JWH-193;
761	748		47. JWH-194;
762	749		48. JWH-195;
763	750		49. JWH-196;
764	751		50. JWH-197;
765	752		51. JWH-198;
766	753		52. JWH-199;
767	754		53. JWH-200;
768	755		54. JWH-201;
769	756		55. JWH-202;
770	757		56. JWH-203;
771	758		57. JWH-204;
772		-	58. JWH-205;
773		-	59. JWH-206;
774		-	60. JWH-207;
775	759
776		-	SENATE FLOOR VERSION - SB1216 SFLR Page 16
777		-	(Bold face denotes Committee Amendments) 1
	760	+	Req. No. 2394 Page 16 1
778	761		2
779	762		3
780	763		4
781	764		5
782	765		6
783	766		7
784	767		8
785	768		9
786	769		10
787	770		11
788	771		12
789	772		13
790	773		14
791	774		15
792	775		16
793	776		17
794	777		18
795	778		19
796	779		20
797	780		21
798	781		22
799	782		23
800	783		24
801	784
	785	+	58. JWH-205;
	786	+	59. JWH-206;
	787	+	60. JWH-207;
802	788		61. JWH-208;
803	789		62. JWH-209;
804	790		63. JWH-210;
805	791		64. JWH-211;
806	792		65. JWH-212;
807	793		66. JWH-213;
808	794		67. JWH-234;
809	795		68. JWH-235;
810	796		69. JWH-236;
811	797		70. JWH-237;
812	798		71. JWH-239;
813	799		72. JWH-240;
814	800		73. JWH-241;
815	801		74. JWH-242;
816	802		75. JWH-243;
817	803		76. JWH-244;
818	804		77. JWH-245;
819	805		78. JWH-246;
820	806		79. JWH-248;
821	807		80. JWH-249;
822	808		81. JWH-250;
823		-	82. JWH-251;
824		-	83. JWH-252;
825		-	84. JWH-253;
826	809
827		-	SENATE FLOOR VERSION - SB1216 SFLR Page 17
828		-	(Bold face denotes Committee Amendments) 1
	810	+	Req. No. 2394 Page 17 1
829	811		2
830	812		3
831	813		4
832	814		5
833	815		6
834	816		7
835	817		8
836	818		9
837	819		10
838	820		11
839	821		12
840	822		13
841	823		14
842	824		15
843	825		16
844	826		17
845	827		18
846	828		19
847	829		20
848	830		21
849	831		22
850	832		23
851	833		24
852	834
	835	+	82. JWH-251;
	836	+	83. JWH-252;
	837	+	84. JWH-253;
853	838		85. JWH-262;
854	839		86. JWH-292;
855	840		87. JWH-293;
856	841		88. JWH-302;
857	842		89. JWH-303;
858	843		90. JWH-304;
859	844		91. JWH-305;
860	845		92. JWH-306;
861	846		93. JWH-307;
862	847		94. JWH-308;
863	848		95. JWH-311;
864	849		96. JWH-312;
865	850		97. JWH-313;
866	851		98. JWH-314;
867	852		99. JWH-315;
868	853		100. JWH-316;
869	854		101. JWH-346;
870	855		102. JWH-348;
871	856		103. JWH-363;
872	857		104. JWH-364;
873	858		105. JWH-365;
874		-	106. JWH-367;
875		-	107. JWH-368;
876		-	108. JWH-369;
877	859
878		-	SENATE FLOOR VERSION - SB1216 SFLR Page 18
879		-	(Bold face denotes Committee Amendments) 1
	860	+	Req. No. 2394 Page 18 1
880	861		2
881	862		3
882	863		4
883	864		5
884	865		6
885	866		7
886	867		8
887	868		9
888	869		10
889	870		11
890	871		12
891	872		13
892	873		14
893	874		15
894	875		16
895	876		17
896	877		18
897	878		19
898	879		20
899	880		21
900	881		22
901	882		23
902	883		24
903	884
	885	+	106. JWH-367;
	886	+	107. JWH-368;
	887	+	108. JWH-369;
904	888		109. JWH-370;
905	889		110. JWH-371;
906	890		111. JWH-373;
907	891		112. JWH-386;
908	892		113. JWH-387;
909	893		114. JWH-392;
910	894		115. JWH-394;
911	895		116. JWH-395;
912	896		117. JWH-397;
913	897		118. JWH-398;
914	898		119. JWH-399;
915	899		120. JWH-400;
916	900		121. JWH-412;
917	901		122. JWH-413;
918	902		123. JWH-414;
919	903		124. JWH-415;
920	904		125. CP-55, 940;
921	905		126. CP-47, 497;
922	906		127. HU-210;
923	907		128. HU-211;
924	908		129. WIN-55, 212-2;
925		-	130. AM-2201;
926		-	131. AM-2233;
927		-	132. JWH-018 adamantyl-carboxamide;
928	909
929		-	SENATE FLOOR VERSION - SB1216 SFLR Page 19
930		-	(Bold face denotes Committee Amendments) 1
	910	+	Req. No. 2394 Page 19 1
931	911		2
932	912		3
933	913		4
934	914		5
935	915		6
936	916		7
937	917		8
938	918		9
939	919		10
940	920		11
941	921		12
942	922		13
943	923		14
944	924		15
945	925		16
946	926		17
947	927		18
948	928		19
949	929		20
950	930		21
951	931		22
952	932		23
953	933		24
954	934
	935	+	130. AM-2201;
	936	+	131. AM-2233;
	937	+	132. JWH-018 adamantyl-carboxamide;
955	938		133. AKB48;
956	939		134. JWH-122 N-(4-pentenyl)analog;
957	940		135. MAM2201;
958	941		136. URB597;
959	942		137. URB602;
960	943		138. URB754;
961	944		139. UR144;
962	945		140. XLR11;
963	946		141. A-796,260;
964	947		142. STS-135;
965	948		143. AB-FUBINACA;
966	949		144. AB-PINACA;
967	950		145. PB-22;
968	951		146. AKB48 N-5-Fluorpentyl;
969	952		147. AM1248;
970	953		148. FUB-PB-22;
971	954		149. ADB-FUBINACA;
972	955		150. BB-22;
973	956		151. 5-Fluoro PB-22; or
974	957		152. 5-Fluoro AKB-48.
975		-	G. In addition to those substances liste d in subsection F of
976		-	this section, unless specifically excepted or unless listed in
977		-	another schedule, any material, compound, mixture, or prepara tion
978	958
979		-	SENATE FLOOR VERSION - SB1216 SFLR Page 20
980		-	(Bold face denotes Committee Amendments) 1
	959	+	Req. No. 2394 Page 20 1
981	960		2
982	961		3
983	962		4
984	963		5
985	964		6
986	965		7
987	966		8
988	967		9
989	968		10
990	969		11
991	970		12
992	971		13
993	972		14
994	973		15
995	974		16
996	975		17
997	976		18
998	977		19
999	978		20
1000	979		21
1001	980		22
1002	981		23
1003	982		24
1004	983
	984	+	G. In addition to those substances liste d in subsection F of
	985	+	this section, unless specifically excepted or unless listed in
	986	+	another schedule, any material, compound, mixture, or prepara tion
1005	987		which contains any quantity of a synthetic cannabinoid found to be
1006	988		in any of the following chemical groups:
1007	989		1. Naphthoylindoles: any compound containing a 3-(1-
1008	990		naphthoyl)indole structure with or without substitution at the
1009	991		nitrogen atom of the indol e ring by an alkyl, haloalkyl, cyanoalkyl,
1010	992		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
1011	993		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
1012	994		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1013	995		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1014	996		halophenyl group, whether or not further substituted on the indole
1015	997		ring to any extent, and whether or not substituted on the naphthyl
1016	998		ring to any extent. Naphthoylindoles include, but are not limited
1017	999		to:
1018	1000		a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
1019	1001		200),
1020	1002		b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
1021	1003		c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
1022	1004		d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
1023	1005		e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
1024	1006		f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
1025	1007		g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
1026		-	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
1027		-	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
1028		-	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
1029	1008
1030		-	SENATE FLOOR VERSION - SB1216 SFLR Page 21
1031		-	(Bold face denotes Committee Amendments) 1
	1009	+	Req. No. 2394 Page 21 1
1032	1010		2
1033	1011		3
1034	1012		4
1035	1013		5
1036	1014		6
1037	1015		7
1038	1016		8
1039	1017		9
1040	1018		10
1041	1019		11
1042	1020		12
1043	1021		13
1044	1022		14
1045	1023		15
1046	1024		16
1047	1025		17
1048	1026		18
1049	1027		19
1050	1028		20
1051	1029		21
1052	1030		22
1053	1031		23
1054	1032		24
1055	1033
	1034	+	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
	1035	+	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
	1036	+	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
1056	1037		k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
1057	1038		l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
1058	1039		m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
1059	1040		(JWH-098),
1060	1041		n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
1061	1042		o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
1062	1043		naphthoyl)indole (AM-1220),
1063	1044		p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
1064	1045		(MAM-2201), or
1065	1046		q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
1066	1047		2. Naphthylmethylindoles: any compound containing a 1H-indol-3-
1067	1048		yl-(1-naphthyl)methane structure with or without substitution at the
1068	1049		nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
1069	1050		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halob enzyl, 1-
1070	1051		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
1071	1052		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1072	1053		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1073	1054		halophenyl group, whether or not further substituted on the indole
1074	1055		ring to any extent, and whether or not substituted on the naphthyl
1075	1056		ring to any extent. Naphthylmethylindoles include, but are not
1076	1057		limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);
1077		-	3. Naphthoylpyrroles: any compound containing a 3-(1-
1078		-	naphthoyl)pyrrole structure with or without substitution at the
1079		-	nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
1080	1058
1081		-	SENATE FLOOR VERSION - SB1216 SFLR Page 22
1082		-	(Bold face denotes Committee Amendments) 1
	1059	+	Req. No. 2394 Page 22 1
1083	1060		2
1084	1061		3
1085	1062		4
1086	1063		5
1087	1064		6
1088	1065		7
1089	1066		8
1090	1067		9
1091	1068		10
1092	1069		11
1093	1070		12
1094	1071		13
1095	1072		14
1096	1073		15
1097	1074		16
1098	1075		17
1099	1076		18
1100	1077		19
1101	1078		20
1102	1079		21
1103	1080		22
1104	1081		23
1105	1082		24
1106	1083
	1084	+	3. Naphthoylpyrroles: any compound containing a 3-(1-
	1085	+	naphthoyl)pyrrole structure with or without substitution at the
	1086	+	nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
1107	1087		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1108	1088		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1109	1089		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
1110	1090		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1111	1091		phenyl, or halophenyl group, whether or not further substituted on
1112	1092		the pyrrole ring to any extent, and whether or not substituted on
1113	1093		the naphthyl group to any extent. Naphthoylpyrroles include, but
1114	1094		are not limited to:
1115	1095		a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
1116	1096		b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
1117	1097		(JWH-370),
1118	1098		c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
1119	1099		d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);
1120	1100		4. Naphthylideneindenes: any compound containing a 1-(1-
1121	1101		naphthylmethylene)indene structure with or without substitution at
1122	1102		the 3-position of the indene ring by a n alkyl, haloalkyl,
1123	1103		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl,
1124	1104		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1125	1105		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
1126	1106		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1127	1107		phenyl, or halophenyl group, whether or not further substituted on
1128		-	the indene group to any extent, and whether or not substituted on
1129		-	the naphthyl group to any extent. Naphthylmethylindenes include,
1130	1108
1131		-	SENATE FLOOR VERSION - SB1216 SFLR Page 23
1132		-	(Bold face denotes Committee Amendments) 1
	1109	+	Req. No. 2394 Page 23 1
1133	1110		2
1134	1111		3
1135	1112		4
1136	1113		5
1137	1114		6
1138	1115		7
1139	1116		8
1140	1117		9
1141	1118		10
1142	1119		11
1143	1120		12
1144	1121		13
1145	1122		14
1146	1123		15
1147	1124		16
1148	1125		17
1149	1126		18
1150	1127		19
1151	1128		20
1152	1129		21
1153	1130		22
1154	1131		23
1155	1132		24
1156	1133
	1134	+	the indene group to any extent, and whether or not substituted on
	1135	+	the naphthyl group to any extent. Naphthylmethylindenes include,
1157	1136		but are not limited to, (1-[(3-pentyl)-1H-inden-1-
1158	1137		ylidene)methyl]naphthalene (JWH-176);
1159	1138		5. Phenylacetylindoles: any compound containing a 3-
1160	1139		phenylacetylindole structure with or without substitution a t the
1161	1140		nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
1162	1141		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
1163	1142		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
1164	1143		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1165	1144		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1166	1145		halophenyl group, whether or no t further substituted on the indole
1167	1146		ring to any extent, and whethe r or not substituted on the phenyl
1168	1147		ring to any extent. Phenylacetylindoles include, but are not
1169	1148		limited to:
1170	1149		a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
1171	1150		b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
1172	1151		(RCS-8),
1173	1152		c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
1174	1153		d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
1175	1154		e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
1176	1155		f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
1177	1156		6. Cyclohexylphenols: any compound containing a 2-(3-
1178	1157		hydroxycyclohexyl)phenol struc ture with or without substitution at
1179		-	the 5-position of the pheno lic ring by an alkyl, haloalkyl,
1180		-	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1181	1158
1182		-	SENATE FLOOR VERSION - SB1216 SFLR Page 24
1183		-	(Bold face denotes Committee Amendments) 1
	1159	+	Req. No. 2394 Page 24 1
1184	1160		2
1185	1161		3
1186	1162		4
1187	1163		5
1188	1164		6
1189	1165		7
1190	1166		8
1191	1167		9
1192	1168		10
1193	1169		11
1194	1170		12
1195	1171		13
1196	1172		14
1197	1173		15
1198	1174		16
1199	1175		17
1200	1176		18
1201	1177		19
1202	1178		20
1203	1179		21
1204	1180		22
1205	1181		23
1206	1182		24
1207	1183
	1184	+	the 5-position of the phenolic r ing by an alkyl, haloalkyl,
	1185	+	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1208	1186		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1209	1187		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
1210	1188		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
1211	1189		phenyl, or halophenyl group, and whether or not further substituted
1212	1190		on the cyclohexyl ring to any extent. Cyclohexylphenols include,
1213	1191		but are not limited to:
1214	1192		a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
1215	1193		hydroxycyclohexyl]-phenol (CP-47,497),
1216	1194		b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
1217	1195		phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
1218	1196		or
1219	1197		c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
1220	1198		hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
1221	1199		7. Benzoylindoles: any compound conta ining a 3-(benzoyl)indole
1222	1200		structure with or without substitution at the nitrogen atom of the
1223	1201		indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1224	1202		cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
1225	1203		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1226	1204		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1227	1205		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1228	1206		halophenyl group, whether or not further substituted on the indole
1229	1207		ring to any extent, and whether or not substituted on the phenyl
1230		-	group to any extent. Benzoylindoles include, but are not limited
1231		-	to:
1232	1208
1233		-	SENATE FLOOR VERSION - SB1216 SFLR Page 25
1234		-	(Bold face denotes Committee Amendments) 1
	1209	+	Req. No. 2394 Page 25 1
1235	1210		2
1236	1211		3
1237	1212		4
1238	1213		5
1239	1214		6
1240	1215		7
1241	1216		8
1242	1217		9
1243	1218		10
1244	1219		11
1245	1220		12
1246	1221		13
1247	1222		14
1248	1223		15
1249	1224		16
1250	1225		17
1251	1226		18
1252	1227		19
1253	1228		20
1254	1229		21
1255	1230		22
1256	1231		23
1257	1232		24
1258	1233
	1234	+	group to any extent. Benzoylindoles include, but are not limited
	1235	+	to:
1259	1236		a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
1260	1237		b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
1261	1238		methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
1262	1239		c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
1263	1240		d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
1264	1241		e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
1265	1242		iodobenzoyl)indole (AM-2233);
1266	1243		8. Cyclopropoylindoles: Any compound containing a 3-
1267	1244		(cyclopropoyl)indole structure with substitutio n at the nitrogen
1268	1245		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1269	1246		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
1270	1247		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1271	1248		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1272	1249		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1273	1250		halophenyl group, whether or not further substituted in the indole
1274	1251		ring to any extent and whether or not substituted in t he
1275	1252		cyclopropoyl ring to any extent. Cyclopropoylindoles inclu de, but
1276	1253		are not limited to:
1277	1254		a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
1278	1255		(UR-144),
1279	1256		b. 1-(5-chloropentyl)-3-(2,2,3,3-
1280	1257		tetramethylcyclopropoyl)indole (5Cl -UR-144), or
1281		-	c. 1-(5-fluoropentyl)-3-(2,2,3,3-
1282		-	tetramethylcyclopropoyl)indole (XLR11);
1283	1258
1284		-	SENATE FLOOR VERSION - SB1216 SFLR Page 26
1285		-	(Bold face denotes Committee Amendments) 1
	1259	+	Req. No. 2394 Page 26 1
1286	1260		2
1287	1261		3
1288	1262		4
1289	1263		5
1290	1264		6
1291	1265		7
1292	1266		8
1293	1267		9
1294	1268		10
1295	1269		11
1296	1270		12
1297	1271		13
1298	1272		14
1299	1273		15
1300	1274		16
1301	1275		17
1302	1276		18
1303	1277		19
1304	1278		20
1305	1279		21
1306	1280		22
1307	1281		23
1308	1282		24
1309	1283
	1284	+	c. 1-(5-fluoropentyl)-3-(2,2,3,3-
	1285	+	tetramethylcyclopropoyl)indole (XLR11);
1310	1286		9. Indole Amides: Any compound containing a 1H-Indole-3-
1311	1287		carboxamide structure with or without substitution at the nitrogen
1312	1288		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1313	1289		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
1314	1290		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1315	1291		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
1316	1292		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1317	1293		halophenyl group, whethe r or not substituted at the carboxamide
1318	1294		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1319	1295		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1320	1296		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1321	1297		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1322	1298		further substituted in the indole, adamantyl, naphthyl, phenyl,
1323	1299		pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
1324	1300		Amides include, but are not limited to:
1325	1301		a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
1326	1302		(2NE1),
1327	1303		b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
1328	1304		carboxamide (STS-135),
1329	1305		c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
1330	1306		indole-3-carboxamide (ADBICA),
1331		-	d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
1332		-	fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
1333	1307
1334		-	SENATE FLOOR VERSION - SB1216 SFLR Page 27
1335		-	(Bold face denotes Committee Amendments) 1
	1308	+	Req. No. 2394 Page 27 1
1336	1309		2
1337	1310		3
1338	1311		4
1339	1312		5
1340	1313		6
1341	1314		7
1342	1315		8
1343	1316		9
1344	1317		10
1345	1318		11
1346	1319		12
1347	1320		13
1348	1321		14
1349	1322		15
1350	1323		16
1351	1324		17
1352	1325		18
1353	1326		19
1354	1327		20
1355	1328		21
1356	1329		22
1357	1330		23
1358	1331		24
1359	1332
	1333	+	d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
	1334	+	fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
1360	1335		e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
1361	1336		(NNE1),
1362	1337		f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
1363	1338		carboxamide (5F-NNE1),
1364	1339		g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
1365	1340		or
1366	1341		h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
1367	1342		(5F-SDB-006);
1368	1343		10. Indole Esters: Any compound containing a 1H-Indole-3-
1369	1344		carboxylate structure with or without substitution at the nitrogen
1370	1345		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1371	1346		cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1-(N-methyl-
1372	1347		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1373	1348		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1374	1349		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1375	1350		halophenyl group, whet her or not substituted at the carboxylate
1376	1351		group by an adamantyl, naphthy l, phenyl, benzyl, q uinolinyl,
1377	1352		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1378	1353		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1379	1354		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1380	1355		further substituted in the in dole, adamantyl, nap hthyl, phenyl,
1381		-	pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
1382		-	Esters include, but are not limited to:
1383	1356
1384		-	SENATE FLOOR VERSION - SB1216 SFLR Page 28
1385		-	(Bold face denotes Committee Amendments) 1
	1357	+	Req. No. 2394 Page 28 1
1386	1358		2
1387	1359		3
1388	1360		4
1389	1361		5
1390	1362		6
1391	1363		7
1392	1364		8
1393	1365		9
1394	1366		10
1395	1367		11
1396	1368		12
1397	1369		13
1398	1370		14
1399	1371		15
1400	1372		16
1401	1373		17
1402	1374		18
1403	1375		19
1404	1376		20
1405	1377		21
1406	1378		22
1407	1379		23
1408	1380		24
1409	1381
	1382	+	pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
	1383	+	Esters include, but are not limited to:
1410	1384		a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
1411	1385		22),
1412	1386		b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
1413	1387		carboxylate (5F-PB-22),
1414	1388		c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
1415	1389		carboxylate (BB-22),
1416	1390		d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
1417	1391		carboxylate (FDU-PB-22), or
1418	1392		e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
1419	1393		carboxylate (NM2201);
1420	1394		11. Adamantanoylindoles: Any compound containing an
1421	1395		adamantanyl-(1H-indol-3-yl)methanone structure with or without
1422	1396		substitution at the ni trogen atom of the indole ring by an alkyl,
1423	1397		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1424	1398		benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1425	1399		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
1426	1400		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1427	1401		phenyl, or halophenyl group, whether or not further substituted in
1428	1402		the indole ring to any extent and whethe r or not substituted in the
1429	1403		adamantyl ring to any extent. Adamantanoylindoles include, but are
1430	1404		not limited to:
1431		-	a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
1432		-	indol-3-yl]methanone (AM1248), or
1433	1405
1434		-	SENATE FLOOR VERSION - SB1216 SFLR Page 29
1435		-	(Bold face denotes Committee Amendments) 1
	1406	+	Req. No. 2394 Page 29 1
1436	1407		2
1437	1408		3
1438	1409		4
1439	1410		5
1440	1411		6
1441	1412		7
1442	1413		8
1443	1414		9
1444	1415		10
1445	1416		11
1446	1417		12
1447	1418		13
1448	1419		14
1449	1420		15
1450	1421		16
1451	1422		17
1452	1423		18
1453	1424		19
1454	1425		20
1455	1426		21
1456	1427		22
1457	1428		23
1458	1429		24
1459	1430
	1431	+	a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
	1432	+	indol-3-yl]methanone (AM1248), or
1460	1433		b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
1461	1434		001);
1462	1435		12. Carbazole Ketone: Any compound containing (9H-carbazole-3-
1463	1436		yl) methanone structure with or without substitution at the nitrogen
1464	1437		atom of the carbazole r ing by an alkyl, haloalkyl, cyanoalkyl,
1465	1438		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
1466	1439		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
1467	1440		2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1468	1441		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1469	1442		halophenyl group, with substitution at the carbon of the m ethanone
1470	1443		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1471	1444		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1472	1445		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1473	1446		dimethyl-1-oxobutan-2-yl or pyrrole group, and wheth er or not
1474	1447		further substituted at the carbazole, adamantyl, naphthyl, phenyl,
1475	1448		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
1476	1449		Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-
1477	1450		9H-carbazol-3-yl)methanone (EG-018);
1478	1451		13. Benzimidazole Ketone: Any compound containing
1479	1452		(benzimidazole-2-yl) methanone structure with or without
1480	1453		substitution at either nitrogen atom of the benzimidazole ring b y an
1481	1454		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
1482		-	cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-
1483		-	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1484	1455
1485		-	SENATE FLOOR VERSION - SB1216 SFLR Page 30
1486		-	(Bold face denotes Committee Amendments) 1
	1456	+	Req. No. 2394 Page 30 1
1487	1457		2
1488	1458		3
1489	1459		4
1490	1460		5
1491	1461		6
1492	1462		7
1493	1463		8
1494	1464		9
1495	1465		10
1496	1466		11
1497	1467		12
1498	1468		13
1499	1469		14
1500	1470		15
1501	1471		16
1502	1472		17
1503	1473		18
1504	1474		19
1505	1475		20
1506	1476		21
1507	1477		22
1508	1478		23
1509	1479		24
1510	1480
	1481	+	cycloalkylethyl, benzyl, halob enzyl, 1-(N-methyl-2-
	1482	+	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
1511	1483		pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
1512	1484		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1513	1485		halophenyl group, with substitution at the carbon of the methan one
1514	1486		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1515	1487		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1516	1488		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1517	1489		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1518	1490		further substituted in the benzimidazole, adamantyl, naphthyl,
1519	1491		phenyl, pyrrole, quinolinyl, o r cycloalkyl rings to any extent.
1520	1492		Benzimidazole Ketones include, but are not limited to:
1521	1493		a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
1522	1494		l)methanone (JWH-018 benzimidazole analog), or
1523	1495		b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
1524	1496		yl)(naphthalen-1-yl)methanone (FUBIMINA); and
1525	1497		14. Modified by Replacement: any compound defined in this
1526	1498		subsection that is modified by replacement of a carbon with nitrogen
1527	1499		in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
1528	1500		H. Any prescription drug approved by the federal Food and Drug
1529	1501		Administration under the pr ovisions of Section 505 of the Federal
1530	1502		Food, Drug and Cosmetic Act, Title 21 of the United States Code,
1531	1503		Section 355, that is designated, rescheduled or deleted as a
1532	1504		controlled substance under federal law by the United States Drug
1533		-	Enforcement Administration shall be exc luded from Schedule I and
1534		-	shall be prescribed, d istributed, dispensed or used in accordance
1535	1505
1536		-	SENATE FLOOR VERSION - SB1216 SFLR Page 31
1537		-	(Bold face denotes Committee Amendments) 1
	1506	+	Req. No. 2394 Page 31 1
1538	1507		2
1539	1508		3
1540	1509		4
1541	1510		5
1542	1511		6
1543	1512		7
1544	1513		8
1545	1514		9
1546	1515		10
1547	1516		11
1548	1517		12
1549	1518		13
1550	1519		14
1551	1520		15
1552	1521		16
1553	1522		17
1554	1523		18
1555	1524		19
1556	1525		20
1557	1526		21
1558	1527		22
1559	1528		23
1560	1529		24
1561	1530
	1531	+	Enforcement Administration shall be exc luded from Schedule I and
	1532	+	shall be prescribed, distributed, dispensed or used in accordance
1562	1533		with federal law upon the issuance of a notice, final rule or
1563	1534		interim final rule by the United Sta tes Drug Enforcement
1564	1535		Administration designating, rescheduling or deleting as a controlled
1565	1536		substance such a drug product under federal law, unless and until
1566	1537		the State Board of Pharmacy takes action pursuant to Section 2-201
1567	1538		of this title. If the Board of Pharmacy does not take action
1568	1539		pursuant to Section 2-201 of this title, the drug product shall be
1569	1540		deemed to be designated, rescheduled or deleted as a controlled
1570	1541		substance in accordance with federal law and in compliance with the
1571	1542		Uniform Controlled Dangerous Subst ances Act.
1572	1543		SECTION 2. This act shall become effective November 1, 2024.
1573		-	~~COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICE S~~
1574		-	~~February 22,~~ ~~2024 - DO PASS~~
	1544	+
	1545	+	59-2-2394 CN 12/4/2023 1:20:37 PM